Genprex (GNPX) Experiences Decline Amid Research Update
Genprex, Inc. (NASDAQ: GNPX) recorded a 3.76 % drop during the 24‑hour trading window that closed at 04:04 PM Central Europe on Thursday, 22 October 2026. The share price, which currently hovers around USD 2.04, reflects a broader downward trend that has persisted for the last month, with a 42.09 % decline since the end of September.
Market Snapshot
| Metric | Value |
|---|---|
| Current Share Price | USD 2.04 |
| Shares Outstanding | 821.6 k |
| Market Capitalisation | USD 1.8 million |
| 24‑Hour Trading Volume | USD 741.3 k |
| 200‑Day Simple Moving Average (SMA) | USD 22.1 |
| 52‑Week High | USD 222.2 (24 Oct 2025) |
| 52‑Week Low | USD 1.91 (21 Oct 2026) |
The company’s share price has slipped significantly from its 200‑day SMA, and the current price sits near the most recent 52‑week low, underscoring a period of volatility for investors.
Recent Scientific Development
On 21 October 2026, Genprex announced that a peer‑reviewed study conducted by researchers at Meharry Medical College has identified the TUSC2 gene—its therapeutic target in the REQORSA® gene‑therapy program—as playing a significant role in brain aging. Published in Mechanisms of Ageing and Development, the study demonstrated that loss of TUSC2 in mice disrupted mitochondrial function, protein homeostasis, and synaptic pathways, with more pronounced effects observed in male animals.
Human gene‑expression analyses indicated that TUSC2 expression decreases with age in most brain regions and is further reduced in Alzheimer’s disease samples. Genprex highlighted these findings as expanding the understanding of TUSC2’s biological functions beyond oncology and suggesting potential relevance for age‑related cognitive disorders. The company emphasized that the study is exploratory and that further work is required to determine therapeutic implications.
Peer Performance in the Last 24 Hours
| Company | Ticker | 24‑Hour Change | Current Price (USD) | Market Cap (USD million) |
|---|---|---|---|---|
| Biorestorative Therapies | BRTX | –1.92 % | 1.62 | 2.1 |
| Nuwellis | NUWE | –5.45 % | 0.51 | 2.0 |
| Geovax Labs | GOVX | +2.20 % | 0.22 | 2.1 |
| Kairos Pharma | KAPA | –1.20 % | 0.59 | 2.0 |
| Oragenics | OGEN | –4.65 % | 0.41 | 2.0 |
The decline in Genprex’s share price is consistent with a broader downward trend among its peer group, although Geovax Labs experienced a modest increase during the same period.
Company Overview
Genprex, Inc. is a biotechnology firm focused on the discovery and development of immunogene therapies for cancer treatment. The company also offers clinical research, gene therapy, consulting, and related medical services to clients in the United States. Genprex’s initial public offering occurred on 29 March 2018, and it is listed on the Nasdaq stock exchange. Further information can be found on its website at www.genprex.com .
